What should be the role of public health in newborn screening and prenatal diagnosis?

American Journal of Preventive Medicine

Volumn 16, Issue 2, 1999, Pages 111-115

  Clayton, Ellen Wright ^a  

^a Medical Center East   (United States)

Author keywords

Newborn screening; Prenatal diagnosis; Public health

Indexed keywords

CONGENITAL MALFORMATION; LABORATORY TEST; MEDICAL PRACTICE; NEWBORN SCREENING; PREGNANCY; PRENATAL DIAGNOSIS; PUBLIC HEALTH; REVIEW;

EID: 0033062155     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(98)00142-1     Document Type: Article

References (20)

1. The future of public health. 1988;National Academy Press, Washington, DC.
2. Clayton E.W. Screening and treatment of newborns. Houston Law Review. 29:1992;85-148.
3. Committee for the Study of Inborn Errors of Metabolism, Division of Medical Sciences, Assembly of Life Sciences, National Research Council, Genetic Screening Programs, Principles, and Research . 1975;National Academy Press, Washington, DC.
4. Reilly P.R. Genetics, law, and society. 1977;Harvard University Press, Cambridge.
5. Newborn screening for cystic fibrosis A paradigm for public health genetics policy development C proceedings of a 1997 workshop . MMWR. 46:1997;. (No. RR-16).
6. Wald N.J., Morris J.K. Neonatal screening for cystic fibrosis No evidence yet of any benefits . BMJ. 316:1998;404-405.
7. Therell B.L. Jr, Berenbaum S.A., Manter-Kapanke V., et al. Results of screening 1.0 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 101:1998;583-590.
8. Faden R., Chwalow A.J., Holtzman N.A., Horn S.D. A survey to evaluate parental consent as public policy for neonatal screening. Am J Publ Health. 72:1982;1347-1352.
9. Annas G.J. Mandatory PKU screening The other side of the looking glass . Am J Publ Health. 72:1982;1401-1403.
10. U.S. Department of Health and Human Services, Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. U.S. Public Health Service 91-50212.
11. Cal. Admin. Code tit. 17§§ 6521-6532 (1998).
12. Levine L.S., Pang S. Prenatal diagnosis and treatment of congenital adrenal hyperplasia. J Ped Endocrin. 7:1994;193-200.
13. Forouzan I. Hydrops fetalis Recent advances . Obstet Gynecol Survey. 52:1997;130-138.
14. Clayton E.W. What the law says about reproductive genetic testing and what it doesn't, In Rothenberg K, Thomson E, editors . Women and prenatal testing Facing the challenges of genetic technology . 1994;131-178 Ohio State University Press, Columbus, OH.
15. Cunningham G.C., Kizer K.W. Maternal serum alpha-feto protein activities of state health agencies A survey . Am J Hum Genet. 47:1990;899-903.
16. Kaplan D. Prenatal screening and diagnosis The impact on persons with disabilities . Rothenberg K., Thomson E. Women and prenatal testing Facing the challenges of genetic technology . 1994;49-61 Ohio State University Press, Columbus, OH.
17. Tosi L.L., Detsky A.S., Roye D.P., Morden M.L. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings? Can Med Assoc J. 136:1987;255-265.
18. Genetic Testing for Cystic Fibrosis. NIH Consensus Statement 1997 Apr 14-16; 15(4):1-37.
19. Office of Genetics and Disease Prevention, at the Centers for Disease Control and Prevention. Translating Advances in Human Genetics Into Public Health Action: A Strategic Plan. http://www.cdc.gov/genetics/Stratpl.html.
20. Task Force on Genetic Testing, NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research. Promoting safe and effective genetic testing in the United States: Principles and recommendations. http://www.med.jhu.edu/tfgelsi/promoting.